Authorized purpose: Manages, views, processes, stores, transfers, filters, manipulates, and quantitatively measures DICOM and non-DICOM images and data, with optional Cardio AI and Oncology AI support.
Clinical role
Image display, processing and quantitative measurement software whose deep learning automation (segmentation, landmark identification) produces on-screen results the user reviews and edits; it provides information a trained professional interprets and does not directly generate diagnoses or findings.
Images and patients
CT/CTA; MRI · Multi-region
Key limitation
Keep in mind: Support tool only, requiring professional interpretation and user review or editing; optional-module and stated 1.5T/3T validation scope apply.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Manages, views, processes, stores, transfers, filters, manipulates, and quantitatively measures DICOM and non-DICOM images and data, with optional Cardio AI and Oncology AI support.
Which images or clinical context are in scope?Modality: CT/CTA; MRI Anatomy or clinical context: Multi-region Input: PACS or scanner DICOM and non-DICOM data; Cardio AI uses multi-slice, multi-phase velocity-encoded MR validated at 1.5T and 3T.
Who uses it?Intended users: Trained healthcare professionals, with clinicians retaining final responsibility.
What does the software produce?Output: Blood-flow and ventricular-function metrics, perfusion and delayed-enhancement data, parametric maps, user-modifiable contours, and oncology lesion evaluation, quantification, follow-up, and documentation.
What is its most important limitation?Key limitation: Support tool only, requiring professional interpretation and user review or editing; optional-module and stated 1.5T/3T validation scope apply.
Clinical takeaway. Clinical role: Manages, views, processes, stores, transfers, filters, manipulates, and quantitatively measures DICOM and non-DICOM images and data, with optional Cardio AI and Oncology AI support.
Evidence takeaway. Evidence from the reviewed source record: Software verification and validation included T1/T2 difference requirements within 30 ms and 4 ms and standalone assessment of 90 cardiac T1-mapping SAX scans from 16 studies.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Manages, views, processes, stores, transfers, filters, manipulates, and quantitatively measures DICOM and non-DICOM images and data, with optional Cardio AI and Oncology AI support.
Exact FDA submission
Checked 2026-09-15
Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.
Image display, processing and quantitative measurement software whose deep learning automation (segmentation, landmark identification) produces on-screen results the user reviews and edits; it provides information a trained professional interprets and does not directly generate diagnoses or findings.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Arterys® MICA software is a medical diagnostic application that displays, processes, stores, and transfers DICOM and non-DICOM medical data. It provides the capability to store images and patient information, and perform filtering, digital manipulation, and quantitative measurements." … "Arterys MICA uses many deep learning algorithms to reduce many tedious, time-consuming manual steps, such as segmentation, landmark identification, etc. The results of these AI models are available on-screen to the user for further review and editing.". Read from the exact FDA decision document on 2026-11-14.
Blood-flow and ventricular-function metrics, perfusion and delayed-enhancement data, parametric maps, user-modifiable contours, and oncology lesion evaluation, quantification, follow-up, and documentation.
Software verification and validation included T1/T2 difference requirements within 30 ms and 4 ms and standalone assessment of 90 cardiac T1-mapping SAX scans from 16 studies.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Software verification and validation included T1/T2 difference requirements within 30 ms and 4 ms and standalone assessment of 90 cardiac T1-mapping SAX scans from 16 studies.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Arterys MICA regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K203744
Samplen=16
IndependenceIndependence not established
K203744
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K203744. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: PACS or scanner DICOM and non-DICOM data; Cardio AI uses multi-slice, multi-phase velocity-encoded MR validated at 1.5T and 3T.
Scope: Exact FDA submission. FDA packet input scope.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
Scope: Exact FDA submission. Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes Arterys MICA as completely hosted in the cloud and accessed using a compatible web browser, with client software designed to run on standard personal and business computers. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Arterys MICA is completely hosted in the cloud and is accessed using a compatible web browser by navigating to the following https://app.arterys.com." … "The client software is designed to run on standard personal and business computers". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Blood-flow and ventricular-function metrics, perfusion and delayed-enhancement data, parametric maps, user-modifiable contours, and oncology lesion evaluation, quantification, follow-up, and documentation.
Scope: Exact FDA submission. FDA packet output scope.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Blood-flow and ventricular-function metrics, perfusion and delayed-enhancement data, parametric maps, user-modifiable contours, and oncology lesion evaluation, quantification, follow-up, and documentation.
Scope: Exact FDA submission. FDA packet output scope.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes Arterys MICA as completely hosted in the cloud and accessed using a compatible web browser, with client software designed to run on standard personal and business computers. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Arterys MICA is completely hosted in the cloud and is accessed using a compatible web browser by navigating to the following https://app.arterys.com." … "The client software is designed to run on standard personal and business computers". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
Exact FDA submission
Checked 2026-09-01
Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.
Tempus's responsible disclosure policy commits to vulnerability intake for any of its assets (tempus.com and public internet-facing and cloud infrastructure it operates), coordinated handling with a 90-day disclosure window, timely correction, and a safe-harbor commitment for good-faith research. Arterys' own site states Arterys has joined Tempus as Tempus Radiology.
Vendor-wide
Checked 2026-10-27
Vendor statement. Entity bridge: arterys.com announces 'Arterys has joined Tempus... as Tempus Radiology'. The Tempus policy is an organizational vulnerability-handling statement; no certification or audit report was read, and exact-release scope is not established.
Tempus' responsible disclosure policy, covering Tempus assets and operated infrastructure, states vulnerability intake with a 90-day coordinated disclosure window and a timely correction commitment.
Vendor-wide
Checked 2026-10-27
Vendor statement, not an attestation. The policy names Tempus generally and does not scope these commitments to any specific product release; exact-release scope is not established.
ACR AI Central provides an exact-submission model card for Arterys MICA; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Care setting: Not publicly available - checked 2026-11-14 - Exact FDA submission
The exact FDA decision document was reviewed on 2026-11-14 and does not state a care setting or patient population for the subject device. Confirm intended sites and patients with the vendor and local policy.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K203744 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Authorized purpose: Support-tool image processing for quantitative cardiovascular assessment and oncologic lesion evaluation, quantification, follow-up, and documentation to aid trained healthcare professionals in diagnosis; the software does not directly generate a diagnosis or potential findings.
Modality
CT/CTA; MRI
Anatomy
Heart and major vessels for Cardio AI; oncology lesion anatomy is not further specified in the FDA statement.
Authorized purpose: DICOM/non-DICOM image and data management with optional quantitative cardiac MR and oncology lesion evaluation, quantification, follow-up, and documentation support; the software does not directly generate a diagnosis or potential findings.
Modality
CT/CTA; MRI
Anatomy
Heart and major vessels for the optional Cardio AI module; lung and liver lesions or nodules for the optional Oncology AI module; the base viewer handles broader radiological image data.
Authorized purpose: Oncology imaging workflow for viewing, manipulating, 3D visualizing, and comparing images and assessing/documenting morphological changes at diagnostic and therapy follow-up; supports lesion evaluation, quantification, follow-up, and documentation.
Modality
CT/CTA; MRI
Anatomy
Oncologic lesions, with semi-automated segmentation explicitly described for lung nodules and liver lesions.
Authorized purpose: syngo.via MI Workflows, Scenium, and syngo MBF provide PET, SPECT, nuclear-medicine, CT, and MR viewing, manipulation, quantification, longitudinal comparison, and analysis for oncology, cardiology, neurology, organ function, and selected radiation-planning support.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.